<DOC>
	<DOCNO>NCT00946920</DOCNO>
	<brief_summary>A phase 3 , open-label , parallel group , one year trial compare efficacy safety degarelix 3-month depot establish therapy goserelin acetate 3-month implant patient prostate cancer .</brief_summary>
	<brief_title>A Trial Degarelix Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>18 year old . Has histological confirm prostate cancer Gleason grade ) . Has screen testosterone 2.2 ng/mL . Rising prostatespecific antigen ( PSA ) . Has Eastern Cooperative Oncology Group ( ECOG ) score â‰¤ 2 . Has life expectancy least one year . Current previous hormone therapy . Has receive therapy finasteride dutasteride within 12 week 25 week , respectively , prior screening . Has history severe untreated asthma , anaphylactic reaction , severe urticaria and/or angioedema . Has heart insufficiency . Has previous history presence another malignancy , prostate cancer treat squamous/basal cell carcinoma skin , within last five year . Has clinically significant medical condition ( prostate cancer ) include , limited , renal , haematological , gastrointestinal , endocrine , cardiac , neurological , psychiatric disease alcohol drug abuse condition may affect patient 's health outcome trial judge Investigator . Has receive investigational drug within last 28 day Screening Visit longer consider possibly influence outcome current trial . Is candidate curative therapy , i.e . radical prostatectomy radiotherapy .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>